LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC decreased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,471 shares of the medical instruments supplier’s stock after selling 462 shares during the quarter. HighTower Advisors LLC’s holdings in LeMaitre Vascular were worth $512,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of LMAT. Driehaus Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares during the period. F M Investments LLC acquired a new position in shares of LeMaitre Vascular in the 2nd quarter valued at $7,443,000. Nicholas Investment Partners LP purchased a new stake in LeMaitre Vascular in the 2nd quarter valued at about $3,900,000. Conestoga Capital Advisors LLC increased its position in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after acquiring an additional 36,850 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its holdings in shares of LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock worth $24,273,000 after acquiring an additional 35,383 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Insider Activity at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.79% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Oppenheimer reissued an “outperform” rating and set a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Trading Down 0.1 %

Shares of LMAT stock opened at $92.12 on Friday. The stock has a 50 day simple moving average of $97.75 and a 200-day simple moving average of $89.91. LeMaitre Vascular, Inc. has a 12-month low of $52.88 and a 12-month high of $109.58. The company has a market cap of $2.07 billion, a price-to-earnings ratio of 50.34, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter in the previous year, the company earned $0.33 EPS. The company’s quarterly revenue was up 15.6% on a year-over-year basis. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st were issued a $0.16 dividend. The ex-dividend date was Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.69%. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.